Cao et al. reported that RES may inhibit human ovarian cancer progression and angiogenesis by inhibiting HIF-1α and VEGF expression through multiple mechanisms, including the inhibition of AKT and mitogen-activated protein kinase activation, the inhibition of several protein translational regulators, and inducing HIF-1α protein degradation through the proteasome pathway [29]. Here, HIF1A is linked to ovarian carcinoma.